NSCLC
Conditions
Keywords
ctDNA-MRD
Brief summary
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
Detailed description
In the phase II trial, the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy will be compared with that of standard adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC.
Interventions
DRUGadjuvant tislelizumab and chemotherapy for MRD+ patients
MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+ adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)
DRUGadjuvant chemotherapy for MRD- patients
MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
Sponsors
BeiGene
The First Affiliated Hospital of Zhengzhou University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patient with age ≥ 18 years old, gender is not limited. 2. Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB. 3. Receiving complete resection 4. Paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required. 5. ECOG score of 0 or 1. 6. Females of childbearing age should take appropriate contraceptive measures from screening to 3 months after discontinuation of study treatment and should not breastfeed. The pregnancy test was negative before starting dosing. 7. Male patients should use barrier contraception from screening to 3 months after discontinuation of study treatment. 8. The subjects themselves participated voluntarily and signed the informed consent in writing.
Exclusion criteria
1. The patient has received immune checkpoint inhibitors such as anti-PD-1, PD-L1 or CTLA-4, other immunotherapy or systemic immune modulators (including but not limited to interferon, IL-2 and TNF etc). 2. Histopathology with small cell or large cell endocrine tumor component. 3. Harboring EGFR sensitizing mutation or ALK gene translocation 4. History of other malignant tumors, except for non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and no evidence of any disease for \>5 years after the last treatment. 5. At the start of the study treatment, there are residual toxicities of the previous treatment that are greater than CTCAE 1 and have not been alleviated, except for alopecia and grade 2 neurotoxicity caused by previous chemotherapy. 6. Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, active bleeding, active infection including hepatitis B, C, HIV, etc., which the investigator considers unsuitable to participate in the study or affect the trial program compliance. 7. History of ILD, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease 8. Insufficient bone marrow reserve or organ function. 9. History of hypersensitivity reactions to any active or inactive ingredient of tislelizumab or to drugs that are chemically similar to tislelizumab or in the same class of tislelizumab. 10. Patients who, in the judgment of the investigator, may not comply with the procedures and requirements of the study. 11. Patients who, in the investigator's judgment, have any condition that compromises patient safety or interferes with the evaluation of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year PFS rate | up to 36 months after enrollment or study close | Progression-free survival (per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first. Subjects who do not have disease progression will be censored at their last valid tumor assessment. PFS rate at 1 year as estimated by Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients changed from MRD+ to MRD- after treatment with tislelizumab for 6 months，12 months | At the end of Cycle 8(each cycle is 21 days)、Cycle 16 (each cycle is 21 days) | Percentage of patients changed from MRD+ to MRD- after treatment with Tislelizumab for 9 months，12months |
Countries
China
Contacts
Primary ContactFeng Li, MD
Backup ContactYu Qi
Outcome results
None listed